Exp Clin Endocrinol Diabetes 2010; 118(1): 31-37
DOI: 10.1055/s-0029-1202273
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Tat-modified Leptin is more Accessible to Hypothalamus through Brain-blood Barrier with a Significant Inhibition of Body-weight Gain in High-fat-diet Fed Mice

C. Zhang 1 , 2 , Z. Su 1 , 2 , B. Zhao 1 , Q. Qu 1 , 2 , Y. Tan 2 , 3 , L. Cai 2 , 3 , X. Li 1 , 2 , 4 , 5
  • 1Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education, Jilin Agricultural University, Changchun, China
  • 2The Chinese-American Research Institute for Diabetic Complications, Wenzhou Medical College, Wenzhou, China
  • 3Departments of Medicine and Radiation Oncology, University of Louisville School of Medicine, Louisville, USA
  • 4Key Laboratory of Biotechnology Pharmaceutical Engineering, Wenzhou Medical College, Wenzhou, China
  • 5National Engineering Research Center for Gene Medicine, Jinan University, Guangzhou, China
Further Information

Publication History

received 28.07.2008 first decision 23.10.2008

accepted 22.01.2009

Publication Date:
26 May 2009 (online)

Abstract

Obesity in human was found mainly due to the poor transportation of leptin through brain-blood barrier (BBB), called as leptin resistance. To produce a leptin capable of penetrating BBB, we have added Tat-PTD(9) to the C terminal of leptin to construct a fusion protein. The fusion Tat-leptin and native leptin genes were synthesized by single-step insertion of a polymerase chain reaction and expressed in Escherichia coli BL21 (RossetaTM). The expressing products were purified and renatured by Ni-NTA affinity chromatography, and identified by the molecular size in SDS-PAGE gel and by its immunoreactivity to specific antibody with Western-blotting assay. To bio-functionally evaluate the fusion protein, Balb/c mice fed with high-fat diet (HFD) were given Tat-leptin, leptin or saline for 19 days. The immunohistochemical staining showed the increases in positive stains for the leptin in the region of hypothalamus of the HFD mice with either Tat-leptin or leptin as compared to saline group, but the staining intensity and frequency in the group with Tat-leptin were stronger and higher than those in the group with leptin. Furthermore, the most efficiency in preventing the body-weight gain caused by HFD was found in Tat-leptin group among these three groups. These results suggest that Tat-modified leptin may become a great potential candidate for the prevention or therapy of obese patients.

References

  • 1 Arch JR, Stock MJ, Trayhurn P. Leptin resistance in obese humans: does it exist and what does it mean?.  Int J Obes Relat Metab Disord. 1998;  22 1159-1163
  • 2 Cao G, Pei W, Ge H. et al . In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis.  J Neurosci. 2002;  22 5423-5431
  • 3 Caro JF, Kolaczynski JW, Nyce MR. et al . Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.  Lancet. 1996;  348 159-161
  • 4 Considine RV, Considine EL, Williams CJ. et al . Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity.  J Clin Invest. 1995;  95 2986-2988
  • 5 Considine RV, Considine EL, Williams CJ. et al . The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations.  Diabetes. 1996a;  45 992-994
  • 6 Considine RV, Considine EL, Williams CJ. et al . Mutation screening and identification of a sequence variation in the human ob gene coding region.  Biochem Biophys Res Commun. 1996b;  220 735-739
  • 7 Dietz GP, Valbuena PC, Dietz B. et al . Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.  Brain Res. 2006;  1082 61-66
  • 8 El-Hage N, Wu G, Ambati J. et al . CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.  J Neuroimmunol. 2006;  178 9-16
  • 9 El-Haschimi K, Lehnert H. Leptin resistance – or why leptin fails to work in obesity.  Exp Clin Endocrinol Diabetes. 2003;  111 2-7
  • 10 Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers.  Expert Opin Drug Deliv. 2008;  5 105-117
  • 11 Gump JM, Dowdy SF. TAT transduction: the molecular mechanism and therapeutic prospects.  Trends Mol Med. 2007;  13 443-448
  • 12 Halaas JL, Gajiwala KS, Maffei M. et al . Weight-reducing effects of the plasma protein encoded by the obese gene.  Science. 1995;  269 543-546
  • 13 Hamilton BS, Paglia D, Kwan AY. et al . Increased obese mRNA expression in omental fat cells from massively obese humans.  Nat Med. 1995;  1 953-956
  • 14 Huq I, Ping YH, Tamilarasu N. et al . Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides.  Biochemistry. 1999;  38 5172-5177
  • 15 Jeong KJ, Lee SY. High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification.  Appl Environ Microbiol. 1999;  65 3027-3032
  • 16 Kim D, Jeon C, Kim JH. et al . Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.  Exp Cell Res. 2006;  312 1277-1288
  • 17 Klein S, Coppack SW, Mohamed-Ali V. et al . Adipose tissue leptin production and plasma leptin kinetics in humans.  Diabetes. 1996;  45 984-987
  • 18 Lindgren M, Hallbrink M, Prochiantz A. et al . Cell-penetrating peptides.  Trends Pharmacol Sci. 2000;  21 99-103
  • 19 Maffei M, Halaas J, Ravussin E. et al . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.  Nat Med. 1995;  1 1155-1161
  • 20 Nagayoshi C, Ishibashi M, Kita Y. et al . Expression, refolding and characterization of human brain serine racemase in Escherichia coli with N-terminal His-tag.  Protein Pept Lett. 2005;  12 487-490
  • 21 Oliveros H, Villamor E. Obesity and mortality in critically ill adults: a systematic review and meta-analysis.  Obesity (Silver Spring). 2008;  16 515-521
  • 22 Pelleymounter MA, Cullen MJ, Baker MB. et al . Effects of the obese gene product on body weight regulation in ob/ob mice.  Science. 1995;  269 540-543
  • 23 Reece EA. Obesity, diabetes, and links to congenital defects: a review of the evidence and recommendations for intervention.  J Matern Fetal Neonatal Med. 2008;  21 173-180
  • 24 Schwartz MW, Peskind E, Raskind M. et al . Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans.  Nat Med. 1996;  2 589-593
  • 25 Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men.  Diabetes. 1996;  45 988-991
  • 26 Sengoku T, Bondada V, Hassane D. et al . Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity.  Exp Neurol. 2004;  188 161-170
  • 27 Shimizu H, Oh IS, Okada S. et al . Leptin resistance and obesity.  Endocr J. 2007;  54 17-26
  • 28 Steinberg GR, Dyck DJ, Calles-Escandon J. et al . Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle.  J Biol Chem. 2002;  277 8854-8860
  • 29 Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems.  Appl Microbiol Biotechnol. 2006;  72 211-222
  • 30 Trogdon JG, Finkelstein EA, Hylands T. et al . Indirect costs of obesity: a review of the current literature.  Obes Rev. 2008; 
  • 31 Van Heek M, Compton DS, France CF. et al . Diet-induced obese mice develop peripheral, but not central, resistance to leptin.  J Clin Invest. 1997;  99 385-390
  • 32 Weigle DS, Bukowski TR, Foster DC. et al . Recombinant ob protein reduces feeding and body weight in the ob/ob mouse.  J Clin Invest. 1995;  96 2065-2070
  • 33 Woodside B, Abizaid A, Jafferali S. Effect of acute food deprivation on lactational infertility in rats is reduced by leptin administration.  Am J Physiol. 1998;  274 R1653-1658
  • 34 Yin W, Cao G, Johnnides MJ. et al . TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF.  Neurobiol Dis. 2006;  21 358-371
  • 35 Zhang Y, Proenca R, Maffei M. et al . Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432

1 * Equal contribution to this work

Correspondence

Dr. X. Li

The Chinese-American Research

Institute for Diabetic Complications

Chashan College Park

Wenzhou

Zhejiang Province

325035 China

Phone: +011/86/136 76 70 17 96

Fax: +011/86/577 86 69 93 50

Email: xiaokunli@163.net

Dr. L. Cai

511 South Floyd Street

MDR 533

Louisville

KY 40202

USA

Phone: +502/852/22 14

Fax: +502/852/56 34

Email: L0cai001@louisville.edu

    >